
BioTech Nation ... with Dr. Moira Gunn
169 episodes — Page 4 of 4
Ep 23010Has Medtech Excluded Persons of Color & Women?? Dr. Patrice Matchaba President, Novartis US Foundation
Dr. Patrice Matchaba, the President of the Novartis US Foundation, shows us how medical technology can create systemic racism, both in the medical field and in human clinical trials.
Ep 23009Safe NON-OPIOID Pain Relief - Is It Possible? Dr. Hernan Bazan, Co-Fdr & CEO, South Rampart Pharma
The next generation of pain relief – non-opioid pain relief - with the goal of being equally powerful pain relief without addiction. Dr Hernan Bazan is the Co-Founder & CEO of South Rampart Pharma in New Orleans.
Ep 23008Long Covid related to Fibromyalgia? Dr. Seth Lederman, Tonix Pharmaceuticals
Dr. Seth Lederman, Co-Founder and CEO of Tonix Pharmaceuticals, tells us that Long Covid may be related to Fibromyalgia. Now recruiting in advanced Human Clinical Trials ... www.tonixpharma.com
Ep 23007The Oxford Dodo? ... Joe Hernandez, Blue Water Vaccines
Even Saturday Night Live couldn’t resist the story of a “genetics engineering company” trying to de-extinct the dodo bird. Blue Water Vaccines, founder and CEO Joe Hernandez tells us about his early quest to develop a universal flu vaccine, bringing him face-to-face – so to speak – with the Oxford Dodo. And of course, he funds decoding its DNA.
Ep 23006Getting Immune Systems to Recognize HER2+ tumors - Dr. Randy Schatzman, President & CEO, Bolt Biotherapeutics
Bolt Biotherapeutics’ Dr. Randy Schatzman talks about the role of myeloid cells in teaching our immune systems to recognize tumors in our own bodies and then eliminate them. Nearly two dozen forms of HER2-related cancers are being studied. (16 mins)
Ep 2300522-45 Getting a Vaccination? What about a nasal spray?
Dr. Robert Coleman, the Co-Founder and CEO of Codagenix, shows us how to precisely engineer viruses to be effective vaccines, which can be delivered nasally – you heard that right – no needle.
Ep 2300323-03 Dr. Rob Ross, CEO, Surface Oncology
Surface Oncology's strategy to improve on the first generation of immuno-oncology drugs. Their Phase 2 trials in lung cancer and liver cancer are underway and recruiting.
Ep 2300123-01 Gene Kinney, President & CEO, Prothena Biosciences
Prothena's 1-2-3 punch for Alzheimer’s + their work in Parkinson’s, ALS, and the role of Amyloids in Down Syndrome
Ep 2205222-52 Edward Humes, Pulitzer Prize Winner, "The Forever Witness"
In a long-form feature from Tech Nation, it’s Pulitzer Prize-winning author, Edward Humes, with “The Forever Witness … How DNA and Genealogy Solved a Cold Case Double Murder.” We get an object lesson in the Three Ages of DNA from a forensic investigation standpoint, and while it reads like a fast-paced Cold Case on steroids – it provides details no fiction writer would dare to make up, including the unexpected involvement of the famous true crimes writer, Ann Rule, and a person whose DNA skills are familiar to fans of the PBS documentary series, “Finding Your Roots with Henry Louis Gates, Jr.”
Ep 2205122-51 Keven Ali, CEO, Organon
A new global company with 64 products, many of which are for women? Kevin Ali is the CEO of Organon.
Ep 2205022-50 Dr. Steve Worland, Co-Founder & CEO, eFFECTOR Therapeutics
Cancer is a hijacker, hijacking cells for its own purposes. And that’s where eFFECTOR Therapeutics is determined to intervene. Dr. Steve Worland, the Co-Founder & CEO, talks about just two of the candidates in its pipeline: One is for Non-small cell lung cancer and another for ER+ breast cancer, with these and other clinical trials enrolling now.
Ep 2204922-49 Dr. Zandy Forbes, Pres & CEO, MeiraGTx
Like the idea of replacing some of your DNA with DNA that works better? And what if you want that new DNA to stop? Dr. Alexandria Forbes, the President & CEO of MeiraGTx, tells us about their work in retinitis pigmentosa and Parkinson’s – two of many clinical trials enrolling right now.
Ep 2202322-48 Dr. Robert Ang, President & CEO, Vor Biopharma
Vor Biopharma has a unique approach to a particular kind of cancer – Acute Myeloid Leukemia – perhaps better known to you, as AML. Dr. Robert Ang is Vor's President & CEO.
Ep 2204722-47 Dr. James Mackay, President & CEO, Aristea Therapeutics
Too much of a good thing spells trouble - in this case, that would be neutrophils – the white blood cells that act as our immune system’s first line of defense. It's called PPP, or Palmoplantar Pustulosis. Dr. James Mackay is the President & CEO of Aristea Therapeutics.
Ep 2204622-46 Dr. Maria Maccecchini, Founder, President & CEO, Annovis Bio
Alzheimer’s, Parkinson’s and ALS, among others, are often grouped as Neurodegenerative Disorders. While they each present a different profile of symptoms, what do they have in common? Dr. Maria Maccecchini, the Founder, President & CEO of Annovis Bio, says, "Sticky proteins".
Ep 2204522-16 Triple-Negative Breast Cancer is the most aggressive of all
Anixa is pioneering a new approach to preventing the truly aggressive triple-negative form of breast cancer. Based on research from Cleveland Clinic, this approach has the potential to treat other breast cancers as well as ovarian cancer. Dr. Amit Kumar is the President & CEO. More information is available at anixa.com.
Ep 22022Dr. George Yancopoulos, CEO, Regeneron
Dr. George Yancopoulosis is the President and Chief Scientific Officer of Regeneron. Regeneron is successful on many levels but is perhaps best known for its Covid treatment, directly infusing antibodies. This, of course, requires innovative science … but how do get students to become scientists? Dr. Yancopoulos has an answer.
Ep 22021Dr. Daniel Bloomfield, Chief Medical Officer, Anthos Therapeutics
Blood clots of any sort are dangerous. So dangerous in fact, that 1 in 4 people die from blood clots - independent of medical condition, medicines they take, or medical procedures they undergo. Dr. Daniel Bloomfield, the Chief Medical Officer of Anthos Therapeutics, describes their approach to preventing bleeding while avoiding blood clotting.
Ep 22020Mark Litton, President & CEO, Athira Pharma
Alzheimer’s, Parkinson’s dementia, and other neurodegenerative diseases continue to be challenging, but now new science has led to a better understanding of the natural repair mechanisms in the brain. This, in turn, has generated new options for innovative treatments, and one such approach has entered late-stage human clinical trials. Dr. Mark Litton is the President and CEO of Athira Pharma.